<p>MiMedx Group, Inc（納斯達克：MDXG - 獲取免費報告）在週二的午盤交易中股價下跌了 5.6%。該公司的股價最低曾達到 6.69 美元，最後交易價為 6.7050 美元。在交易中共成交 487,460 股，較平均交易量 711,903 股下降了 32%。該股此前收盤價為 7.10 美元。</p>
<h2>分析師評級變動</h2>
<p>幾位分析師最近對該公司發佈了報告。華爾街 Zen 在 11 月 2 日的報告中將 MiMedx Group 的評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在週四的研究報告中重申了對 MiMedx Group 股票的 “持有（c+）” 評級。最後，Cantor Fitzgerald 在 7 月 31 日的研究報告中將 MiMedx Group 的股票目標價從 11.00 美元上調至 12.00 美元，並給予該股 “增持” 評級。一位股票研究分析師給予該股 “買入” 評級，另一位則給予 “持有” 評級。根據 MarketBeat 的數據，MiMedx Group 目前的平均評級為 “適度買入”，共識目標價為 12.00 美元。</p>
<p><strong>獲取我們對 MiMedx Group 的最新分析</strong></p>
<h2>MiMedx Group 股價下跌 5.3%</h2>
<p>該公司的 50 日簡單移動平均線為 7.07 美元，200 日簡單移動平均線為 6.85 美元。公司的債務與股本比率為 0.08，速動比率為 3.90，流動比率為 4.39。該公司的市值為 9.9599 億美元，市盈率為 24.87，貝塔值為 1.70。</p>
<p>MiMedx Group（納斯達克：MDXG - 獲取免費報告）最近在 11 月 13 日公佈了其財報。該公司報告本季度每股收益為（0.03）美元。該季度的收入為 6769 萬美元。MiMedx Group 的股本回報率為 28.35%，淨利潤率為 10.38%。研究分析師預計，MiMedx Group, Inc 在當前財政年度的每股收益將達到 0.3 美元。</p>
<h2>MiMedx Group 內部買賣情況</h2>
<p>在其他新聞中，內部人士 Kimberly Maersk-Moller 在 11 月 6 日的交易中出售了 58,300 股該股票。該股票的平均售價為 7.42 美元，總價值為 432,586.00 美元。出售完成後，該內部人士持有 236,982 股公司股票，價值約為 1,758,406.44 美元。這代表其持股比例減少了 19.74%。該交易已在向 SEC 的備案中披露，相關信息可通過 SEC 網站訪問。公司內部人士持有該股票的 1.70%。</p>
<h2>機構投資者對 MiMedx Group 的看法</h2>
<p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Strs Ohio 在第一季度新購入了 MiMedx Group 的股份，價值約為 595,000 美元。Zurcher Kantonalbank Zurich Cantonalbank 在第一季度將其在 MiMedx Group 的持股增加了 18.1%。Zurcher Kantonalbank Zurich Cantonalbank 目前持有 39,713 股公司股票，價值為 302,000 美元，此前在上一季度又購買了 6,090 股。Truist Financial Corp 在第二季度將其在 MiMedx Group 的持股增加了 80.8%。Truist Financial Corp 目前持有 96,250 股公司股票，價值 588,000 美元，此前在上一季度又購買了 43,000 股。Harbor Capital Advisors Inc.在第二季度將其在 MiMedx Group 的持股增加了 12.0%。Harbor Capital Advisors Inc.目前持有 1,169,195 股公司股票，價值 7,144,000 美元，此前在上一季度又購買了 125,519 股。最後，HB Wealth Management LLC 在第二季度新購入了 MiMedx Group 的股份，價值約為 156,000 美元。機構投資者持有該公司 79.15% 的股票。</p>
<h2>MiMedx Group 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>MiMedx Group, Inc 開發和分銷胎盤組織同種異體移植物，適用於醫療保健的各個領域。它利用其專利和專有的 PURION 工藝處理人類胎盤組織，以生產保留組織固有生物特性和調節蛋白的同種異體移植物。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>斯特蘭蒂斯在吉普車上進行高風險投資</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>核能收益：第三季度哪些公司獲勝和失利</li>
<li>什麼是熱門股票？熱門股票的解釋</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
<p>在你考慮投資 MiMedx Group 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
<p>雖然 MiMedx Group 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MDXG

<p>MiMedx Group 的股票（NASDAQ:MDXG）在午盤交易中下跌了 5.6%，交易量較平均水平下降了 32%。分析師的評級意見不一，華爾街 Zen 將評級上調至 “強力買入”，Cantor Fitzgerald 將目標價提高至 12.00 美元。該公司報告季度每股虧損 0.03 美元，收入為 6769 萬美元。注意到內部交易活動和機構投資者的變動，79.15% 的股票由機構持有</p>

<p>MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report)'s stock price traded down 5.6% during mid-day trading on Tuesday . The company traded as low as $6.69 and last traded at $6.7050. 487,460 shares were traded during trading, a decline of 32% from the average session volume of 711,903 shares. The stock had previously closed at $7.10.</p>
<div class="lb-trans"><p>MiMedx Group, Inc（納斯達克：MDXG - 獲取免費報告）在週二的午盤交易中股價下跌了 5.6%。該公司的股價最低曾達到 6.69 美元，最後交易價為 6.7050 美元。在交易中共成交 487,460 股，較平均交易量 711,903 股下降了 32%。該股此前收盤價為 7.10 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several analysts recently issued reports on the company. Wall Street Zen upgraded MiMedx Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday, November 2nd. Weiss Ratings reaffirmed a &#34;hold (c+)&#34; rating on shares of MiMedx Group in a research report on Thursday. Finally, Cantor Fitzgerald increased their price target on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an &#34;overweight&#34; rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat, MiMedx Group presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $12.00.</p>
<div class="lb-trans"><p>幾位分析師最近對該公司發佈了報告。華爾街 Zen 在 11 月 2 日的報告中將 MiMedx Group 的評級從 “買入” 上調至 “強力買入”。Weiss Ratings 在週四的研究報告中重申了對 MiMedx Group 股票的 “持有（c+）” 評級。最後，Cantor Fitzgerald 在 7 月 31 日的研究報告中將 MiMedx Group 的股票目標價從 11.00 美元上調至 12.00 美元，並給予該股 “增持” 評級。一位股票研究分析師給予該股 “買入” 評級，另一位則給予 “持有” 評級。根據 MarketBeat 的數據，MiMedx Group 目前的平均評級為 “適度買入”，共識目標價為 12.00 美元。</p>
</div><p><strong>Get Our Latest Analysis on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 MiMedx Group 的最新分析</strong></p>
</div><h2>MiMedx Group Trading Down 5.3%</h2>
<div class="lb-trans"><h2>MiMedx Group 股價下跌 5.3%</h2>
</div><p>The business's 50-day simple moving average is $7.07 and its 200-day simple moving average is $6.85. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.90 and a current ratio of 4.39. The company has a market capitalization of $995.99 million, a price-to-earnings ratio of 24.87 and a beta of 1.70.</p>
<div class="lb-trans"><p>該公司的 50 日簡單移動平均線為 7.07 美元，200 日簡單移動平均線為 6.85 美元。公司的債務與股本比率為 0.08，速動比率為 3.90，流動比率為 4.39。該公司的市值為 9.9599 億美元，市盈率為 24.87，貝塔值為 1.70。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Monday, November 13th. The company reported ($0.03) earnings per share for the quarter. The company had revenue of $67.69 million during the quarter. MiMedx Group had a return on equity of 28.35% and a net margin of 10.38%. On average, research analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（納斯達克：MDXG - 獲取免費報告）最近在 11 月 13 日公佈了其財報。該公司報告本季度每股收益為（0.03）美元。該季度的收入為 6769 萬美元。MiMedx Group 的股本回報率為 28.35%，淨利潤率為 10.38%。研究分析師預計，MiMedx Group, Inc 在當前財政年度的每股收益將達到 0.3 美元。</p>
</div><h2>Insider Buying and Selling at MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 內部買賣情況</h2>
</div><p>In other news, insider Kimberly Maersk-Moller sold 58,300 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $7.42, for a total value of $432,586.00. Following the completion of the sale, the insider owned 236,982 shares of the company's stock, valued at approximately $1,758,406.44. This represents a 19.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.70% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他新聞中，內部人士 Kimberly Maersk-Moller 在 11 月 6 日的交易中出售了 58,300 股該股票。該股票的平均售價為 7.42 美元，總價值為 432,586.00 美元。出售完成後，該內部人士持有 236,982 股公司股票，價值約為 1,758,406.44 美元。這代表其持股比例減少了 19.74%。該交易已在向 SEC 的備案中披露，相關信息可通過 SEC 網站訪問。公司內部人士持有該股票的 1.70%。</p>
</div><h2>Institutional Investors Weigh In On MiMedx Group</h2>
<div class="lb-trans"><h2>機構投資者對 MiMedx Group 的看法</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new stake in shares of MiMedx Group during the 1st quarter worth approximately $595,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in MiMedx Group by 18.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,713 shares of the company's stock worth $302,000 after buying an additional 6,090 shares during the last quarter. Truist Financial Corp grew its holdings in shares of MiMedx Group by 80.8% during the second quarter. Truist Financial Corp now owns 96,250 shares of the company's stock valued at $588,000 after buying an additional 43,000 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of MiMedx Group by 12.0% during the second quarter. Harbor Capital Advisors Inc. now owns 1,169,195 shares of the company's stock valued at $7,144,000 after buying an additional 125,519 shares during the last quarter. Finally, HB Wealth Management LLC bought a new stake in shares of MiMedx Group during the second quarter worth about $156,000. Institutional investors own 79.15% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近對該公司的持倉進行了調整。Strs Ohio 在第一季度新購入了 MiMedx Group 的股份，價值約為 595,000 美元。Zurcher Kantonalbank Zurich Cantonalbank 在第一季度將其在 MiMedx Group 的持股增加了 18.1%。Zurcher Kantonalbank Zurich Cantonalbank 目前持有 39,713 股公司股票，價值為 302,000 美元，此前在上一季度又購買了 6,090 股。Truist Financial Corp 在第二季度將其在 MiMedx Group 的持股增加了 80.8%。Truist Financial Corp 目前持有 96,250 股公司股票，價值 588,000 美元，此前在上一季度又購買了 43,000 股。Harbor Capital Advisors Inc.在第二季度將其在 MiMedx Group 的持股增加了 12.0%。Harbor Capital Advisors Inc.目前持有 1,169,195 股公司股票，價值 7,144,000 美元，此前在上一季度又購買了 125,519 股。最後，HB Wealth Management LLC 在第二季度新購入了 MiMedx Group 的股份，價值約為 156,000 美元。機構投資者持有該公司 79.15% 的股票。</p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 開發和分銷胎盤組織同種異體移植物，適用於醫療保健的各個領域。它利用其專利和專有的 PURION 工藝處理人類胎盤組織，以生產保留組織固有生物特性和調節蛋白的同種異體移植物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Stellantis Makes a High-Stakes Bet on Jeep</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Nuclear Energy Earnings: Which Names Won and Lost in Q3</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Alphabet: Buffett's Bet on Its Next Phase of Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 MiMedx Group</li>
<li>內部人士賣出解釋：這能否影響你的投資選擇？</li>
<li>斯特蘭蒂斯在吉普車上進行高風險投資</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>核能收益：第三季度哪些公司獲勝和失利</li>
<li>什麼是熱門股票？熱門股票的解釋</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 MiMedx Group 嗎？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 MiMedx Group 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 MiMedx Group 並不在名單上。</p>
</div><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 MiMedx Group 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

MiMedx 集團（NASDAQ:MDXG）股價下跌 5.6% - 接下來會如何發展？